In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy - PubMed
4 hours ago
- #CAR therapy
- #Cancer immunotherapy
- #mRNA delivery
- Erythrocyte-mediated mRNA delivery platform (mRNA-LNP-Ery) developed for in vivo CAR myeloid cell generation.
- mRNA-LNP-Ery selectively delivers mRNA to CD11b+ myeloid cells in the spleen, minimizing hepatocyte uptake.
- Internalization via phagocytosis avoids lysosomal degradation, enhancing cytosolic mRNA translation.
- CAR myeloid cells target HER2 or CD19, adopt proinflammatory phenotype, migrate to tumors, and eliminate cancer cells.
- Therapeutic effect depends on CAR myeloid cell formation in the spleen and interaction with adaptive immunity.
- Repeated mRNA-LNP-Ery administration shows superior antitumor efficacy at lower doses with minimal toxicity.
- Platform enables direct in vivo immune cell programming, advancing CAR myeloid therapies for solid tumors.